28 Liberty Street, 39th Floor
147 articles with BeyondSpring Inc.
BeyondSpring Enrolls First Patient in Phase 2 Study with Plinabulin, Keytruda and Docetaxel in Patients with Metastatic Non-Small Cell Lung Cancer Who Progressed After Immunotherapy
BeyondSpring Inc. today announced that the first patient has been enrolled in BeyondSpring’s Phase 2 investigator-initiated trial with lead asset, Plinabulin, in combination with Merck’s anti-PD-1 therapy Keytruda® (pembrolizumab) and Docetaxel for previously treated patients with metastatic non-small cell lung cancer (NSCLC) and progressive disease after immunotherapy (anti-PD-1 / PD-L1 inhibitor) alone or in combination with platinum-doublet chemotherapy.
BeyondSpring Receives Notifications from Nasdaq Regarding Compliance With Listing Rules
BeyondSpring Inc., a clinical stage global biopharmaceutical company focused on developing innovative cancer therapies, announced that on December 29, 2022, the Company received a written notification from Nasdaq that the Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550.
BeyondSpring Presents Positive Data with Plinabulin for the Prevention of Docetaxel-Induced Neutropenia in Patients with Non-Small Cell Lung Cancer and Breast Cancer at Three Medical Conferences
BeyondSpring Inc. (the “Company” or “BeyondSpring”) (Nasdaq: BYSI) today announced data from the ESMO Asia Congress 2022 and the American Society of Hematology (ASH) Annual Meeting about the use of lead asset, plinabulin, for the prevention of docetaxel-induced neutropenia (DIN) in non-small cell lung cancer (NSCLC) patients.
BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements - November 23, 2022
BeyondSpring Inc. announced that on November 18, 2022, it received a written notification from The Nasdaq Stock Market LLC that the Company is not in compliance with the requirement to maintain a minimum closing bid price of $1.00 per share, as set forth in Nasdaq Listing Rule 5550, because the closing bid price of the Company’s ordinary shares was below $1.00 per share for 30 consecutive business days.
BeyondSpring Presents New Clinical Evidence of Plinabulin Protection of Granulocyte-Monocyte Progenitor Stem Cells for the Prevention of Chemotherapy-Induced Neutropenia at the ESMO Congress 2022
BeyondSpring Inc. announced data from a poster presentation at the ESMO Congress 2022 being held September 9-13, 2022, in Paris, France.
BeyondSpring Presents New Clinical Data in the Chemotherapy-Induced Neutropenia and NSCLC Programs at the 2022 ASCO Annual Meeting
BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a clinical stage global biopharmaceutical company focused on developing innovative cancer therapies to improve clinical outcomes for patients who have a high unmet medical need, today announced three poster presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting being held June 3-7, 2022, in Chicago, Illinois.
BeyondSpring Announces Three Poster Presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting
BeyondSpring Inc. announced three poster presentations relating to lead asset plinabulin at the American Society of Clinical Oncology Annual Meeting being held June 3-7, 2022, in Chicago, Illinois and virtually.
BeyondSpring Files 2021 Annual Report on Form 20-F
BeyondSpring Inc. announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2021 with the U.S. Securities and Exchange Commission on April 14, 2022.
BeyondSpring Announces Fourth Quarter and Year End 2021 Financial Results and Provides a Corporate Update
BeyondSpring Inc. today announced its financial results for the fourth quarter and year ended December 31, 2021 and provided a corporate update.
BeyondSpring to Announce Fourth Quarter and Year End 2021 Financial Results and Host a Conference Call on Thursday, April 14, 2022
BeyondSpring Inc., a global biopharmaceutical company focused on the development of innovative cancer therapies, announced that it will report its financial results for the quarter and year ended December 31, 2021 before market open on Thursday, April 14, 2022.
The job cuts were announced as part of an organizational streamlining initiative that will refocus resources toward the company's highest-value activities.
BeyondSpring Announces Organizational Streamlining
BeyondSpring Pharmaceuticals announced an organizational streamlining initiative focused on prioritizing the Company’s highest value business activities, extending its cash runway and preserving long-term sustainability.
BeyondSpring Announces Third Quarter 2021 Financial Results and Provides a Corporate Update
BeyondSpring Inc. today announced its financial results for the third quarter ended September 30, 2021, and provided an update on recent corporate events.
In the CRL, the FDA indicated that the single registrational trial (106 Phase III) did not provide sufficient proof of efficacy to demonstrate benefit.
The U.S. Food and Drug Administration has a very busy calendar for the end of November and beginning of December. Here’s a look.
BeyondSpring Pharmaceuticals to Present at the 4th Annual Evercore ISI HealthCONx Conference
BeyondSpring today announced that management will participate in a Fireside Chat and host one-on-one investor meetings during the 4th Annual Evercore ISI HealthCONx Conference, taking place November 30-December 2, 2021.
BeyondSpring Appoints Commercial Leader Mark Santos to its Board of Directors
BeyondSpring Pharmaceuticals, a clinical stage biopharmaceutical company focused on the development of innovative cancer therapeutics, announced the appointment of Mark Santos, RPh, to its Board of Directors, effective immediately.
Clinical Catch-Up: October 18-22
10/25/2021It was yet another busy week for clinical trial news. Here’s a look.
BeyondSpring Pharmaceuticals Announces New Patient-Derived Cancer Model Data for Plinabulin Monotherpy at the AACR-NCI-EORTC Virtual International Conference
Plinabulin’s anti-cancer effects were tested against approximately 80 patient-derived tumor models with small cell lung cancer (SCLC) tumor types being the most sensitive to plinabulin monotherapy at IC 70 of 35 nM
BeyondSpring Pharmaceuticals Announces Positive Final Phase 3 DUBLIN-3 Data with the Plinabulin/Docetaxel Combination
BeyondSpring today will have a late-breaking oral presentation at the European Society for Medical Oncology 2021 Congress.